Evaxion to Present Three-Year Phase 2 Efficacy Data for EVX-01 at ESMO 2026

Evaxion A/S (NASDAQ: EVAX) announced it will present three-year clinical efficacy data from its Phase 2 trial of EVX-01, a personalized cancer vaccine, at the ESMO Congress 2026 in October. The data comes from a one-year extension study evaluating EVX-01 in patients with advanced melanoma. Notably, in the third year, a subset of patients received EVX-01 as a stand-alone therapy, providing insight into its efficacy without anti-PD-1 combination treatment. Previously reported two-year data showed an Objective Response Rate (ORR) of 75%, with 12 of 16 patients responding and four achieving a complete response. The company highlighted a 92% durable clinical benefit rate at the two-year mark with no relapses observed. The upcoming presentation will focus on the durability of the immune response and sustained disease control. EVX-01 is designed using Evaxion's AI-Immunology™ platform to target unique tumor neoantigens. The presentation is scheduled for October 24, 2026, at the ESMO Congress in Madrid.